Hippocampal Reduction of α-Synuclein via RNA Interference Improves Neuropathology in Alzheimer’s Disease Mice
Journal of Alzheimer’s Disease · 2023
DOI: 10.3233/jad-230232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2023. Verfasst von André D G Leitão und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of California San Diego, La Jolla, CA, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Background
Alzheimer’s disease (AD) cases are often characterized by the pathological accumulation of α-synuclein (α-syn) in addition to amyloid-β (Aβ) and tau hallmarks. The role of α-syn has been extensively studied in synucleinopathy disorders, but less so in AD. Recent studies have shown that α-syn may also play a role in AD and its downregulation may be protective against the toxic effects of Aβ accumulation.
Objective
We hypothesized that selectively knocking down α-syn via RNA interference improves the neuropathological and biochemical findings in AD mice.
Methods
Here we used amyloid precursor protein transgenic (APP-Tg) mice to model AD and explore pathologic and behavioral phenotypes with knockdown of α-syn using RNA interference. We selectively reduced α-syn levels by stereotaxic bilateral injection of either LV-shRNA α-syn or LV-shRNA-luc (control) into the hippocampus of AD mice.
Results
We found that downregulation of α-syn results in significant reduction in the number of Aβ plaques. In addition, mice treated with LV-shRNA α-syn had amelioration of abnormal microglial activation (Iba1) and astrocytosis (GFAP) phenotypes in AD mice.
Conclusion
Our data suggests a novel link between Aβ and α-syn pathology as well as a new therapeutic angle for targeting AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.
- VA San Diego Healthcare System, La Jolla, CA, USA.
- Department of Physiology and Neuroscience, Alzheimer's Therapeutic Research Institute of the Keck School of Medicine of the University of Southern California, San Diego, CA, USA.
Förderung
- NIA NIH HHS
Zitieren
APA
Leitão, A. D. G., Spencer, B., Sarsoza, F., Ngolab, J., Amalraj, J., Masliah, E., Wu, C., & Rissman, R. A. (2023). Hippocampal Reduction of α-Synuclein via RNA Interference Improves Neuropathology in Alzheimer’s Disease Mice. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-230232
Vancouver
Leitão ADG, Spencer B, Sarsoza F, Ngolab J, Amalraj J, Masliah E, et al. Hippocampal Reduction of α-Synuclein via RNA Interference Improves Neuropathology in Alzheimer’s Disease Mice. Journal of Alzheimer’s Disease. 2023. doi:10.3233/jad-230232
BibTeX
@article{Leito2023,
author = {Leitão, André D G and Spencer, Brian and Sarsoza, Floyd and Ngolab, Jennifer and Amalraj, Jessica and Masliah, Eliezer and Wu, Chengbiao and Rissman, Robert A},
title = {Hippocampal Reduction of α-Synuclein via RNA Interference Improves Neuropathology in Alzheimer’s Disease Mice},
journal = {Journal of Alzheimer’s Disease},
year = {2023},
doi = {10.3233/jad-230232}
}
EUVIMED